A mucoadhesive thermosensitive hydrogel containing erythropoietin as a potential treatment in oral mucositis: in vitro and in vivo studies
- 3 August 2018
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 8 (5) , 1226-1237
Abstract
Oral mucositis (OM) represents a therapeutic challenge frequently encountered in cancer patients undergoing chemotherapy or radiotherapy. Erythropoietin (EPO) has anti-inflammatory, antioxidant, and wound-healing properties and therefore has important roles in the prevention and treatment of OM. In the current study, we developed a thermally sensitive mucoadhesive gel based on trimethyl chitosan (TMC) containing EPO for the treatment of OM. TMCs with various degrees of substitution (DS) were synthesized and mixed with β-glycerophosphate (GP) and characterized for gelation properties by means of rheological analysis. The effects of DS of TMCs and different concentrations of GP on gelation temperature and time were investigated. The mucoadhesive property of the mixtures was also assessed using cattle buccal mucosa. The optimized mixture was loaded with EPO and subjected to in vitro drug release, wash away, in vitro antimicrobial, and wound-healing tests. The effect of EPO-loaded formulation was also investigated in vivo in Sprague-Dawley rats with chemotherapy-induced mucositis. The best properties were obtained with the blend of TMC of 9.8% DS (5%) and GP (20%). EPO was released from the hydrogel during 8 h, and more than 30% of the drug still remained on the mucosa after 3 h of washing the buccal mucosa with phosphate buffer. TMC/GP mixture was characterized by antimicrobial properties. The EPO hydrogel demonstrated in vitro/in vivo wound-healing properties. Therefore, EPO-loaded hydrogel has the potential to be used in the treatment of OM and other oral or subcutaneous wounds.Keywords
Funding Information
- Isfahan University of Medical Sciences (194231)
This publication has 45 references indexed in Scilit:
- Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocolsBMC Oral Health, 2012
- Platelet Lysate Mucohadesive Formulation to Treat Oral Mucositis in Graft Versus Host Disease Patients: A New Therapeutic ApproachAAPS PharmSciTech, 2011
- Biomaterials based on chitin and chitosan in wound dressing applicationsBiotechnology Advances, 2011
- Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcersClinical and Experimental Dermatology, 2010
- Management of Oral Mucositis in Patients Who Have CancerDental Clinics of North America, 2008
- Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositisSupportive Care in Cancer, 2006
- Effects of N‐trimethyl chitosan chloride as an absorption enhancer on properties of insulin liquid suppository in vitro and in vivoJournal of Applied Polymer Science, 2005
- Effects of the tumour necrosis factor‐α inhibitors pentoxifylline and thalidomide in short‐term experimental oral mucositis in hamstersEuropean Journal of Oral Sciences, 2005
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studiesJournal of Controlled Release, 2004